Solid Biosciences Inc has a consensus price target of $12.67, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from William Blair, Barclays, and Citigroup on March 28, 2024, March 18, 2024, and March 15, 2024. With an average price target of $25.67 between William Blair, Barclays, and Citigroup, there's an implied 92.69% upside for Solid Biosciences Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/28/2024 | SLDB | Buy Now | Solid Biosciences | $13.32 | 200.3% | William Blair | Tim Lugo | → $40 | Initiates | → Outperform | Get Alert |
03/18/2024 | SLDB | Buy Now | Solid Biosciences | $13.32 | 57.66% | Barclays | Gena Wang | $8 → $21 | Maintains | Overweight | Get Alert |
03/15/2024 | SLDB | Buy Now | Solid Biosciences | $13.32 | 20.12% | Citigroup | David Hoang | → $16 | Initiates | → Buy | Get Alert |
03/14/2024 | SLDB | Buy Now | Solid Biosciences | $13.32 | 50.15% | Piper Sandler | Allison Bratzel | $8 → $20 | Upgrade | Neutral → Overweight | Get Alert |
03/14/2024 | SLDB | Buy Now | Solid Biosciences | $13.32 | 20.12% | HC Wainwright & Co. | Arthur He | → $16 | Reiterates | Buy → Buy | Get Alert |
03/11/2024 | SLDB | Buy Now | Solid Biosciences | $13.32 | 20.12% | HC Wainwright & Co. | Arthur He | $9 → $16 | Maintains | Buy | Get Alert |
12/08/2023 | SLDB | Buy Now | Solid Biosciences | $13.32 | -32.43% | HC Wainwright & Co. | Swayampakula Ramakanth | → $9 | Initiates | → Buy | Get Alert |
09/22/2023 | SLDB | Buy Now | Solid Biosciences | $13.32 | -62.46% | Cantor Fitzgerald | Charles Duncan | → $5 | Initiates | → Overweight | Get Alert |
11/11/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -39.94% | Barclays | Gena Wang | $2 → $8 | Maintains | Overweight | Get Alert |
11/11/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -39.94% | Piper Sandler | Allison Bratzel | $15 → $8 | Maintains | Neutral | Get Alert |
11/10/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -54.95% | SVB Leerink | Joseph Schwartz | $1 → $6 | Maintains | Market Perform | Get Alert |
10/17/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -92.49% | SVB Leerink | Joseph Schwartz | $180 → $15 | Downgrade | Outperform → Market Perform | Get Alert |
09/30/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | — | JP Morgan | Anupam Rama | — | Upgrade | Underweight → Neutral | Get Alert |
08/12/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -54.95% | Chardan Capital | Geulah Livshits | $105 → $90 | Maintains | Buy | Get Alert |
05/19/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -84.98% | Piper Sandler | Allison Bratzel | $75 → $30 | Maintains | Neutral | Get Alert |
04/28/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -62.46% | Piper Sandler | Allison Bratzel | $90 → $75 | Maintains | Neutral | Get Alert |
04/28/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | 12.61% | SVB Leerink | Joseph Schwartz | $180 → $225 | Maintains | Outperform | Get Alert |
04/28/2022 | SLDB | Buy Now | Solid Biosciences | $13.32 | -47.45% | Chardan Capital | Geulah Livshits | $255 → $105 | Maintains | Buy | Get Alert |
09/24/2021 | SLDB | Buy Now | Solid Biosciences | $13.32 | 27.63% | Chardan Capital | Geulah Livshits | — | Maintains | Buy | Get Alert |
The latest price target for Solid Biosciences (NASDAQ: SLDB) was reported by William Blair on March 28, 2024. The analyst firm set a price target for $40.00 expecting SLDB to rise to within 12 months (a possible 200.30% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Solid Biosciences (NASDAQ: SLDB) was provided by William Blair, and Solid Biosciences initiated their outperform rating.
The last upgrade for Solid Biosciences Inc happened on March 14, 2024 when Piper Sandler raised their price target to $20. Piper Sandler previously had a neutral for Solid Biosciences Inc.
The last downgrade for Solid Biosciences Inc happened on October 17, 2022 when SVB Leerink changed their price target from $12 to $1 for Solid Biosciences Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Solid Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Solid Biosciences was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
While ratings are subjective and will change, the latest Solid Biosciences (SLDB) rating was a initiated with a price target of $0.00 to $40.00. The current price Solid Biosciences (SLDB) is trading at is $13.32, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.